

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037266 A1

(51) International Patent Classification⁷: **A61K 31/196**, A61P 29/00, A61K 9/08, 47/34, 47/10

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP2004/011223

(22) International Filing Date: 7 October 2004 (07.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/509,459 8 October 2003 (08.10.2003) US

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DANNENFELSER, Rose-Marie [US/US]; 45 John Street, #2B, Bloomfield, NJ 07003 (US). GEORGOUSIS, Vivian, Christine [US/US]; 27 Park Stret, West Caldwell, NJ 07006 (US). KHALED, Maha, Y. [US/US]; 27 Pebble Beach Drive, Livingston, NJ 07039 (US). PATEL, Tarun, S. [US/US]; 95 Carlton Drive, Parsippany, NJ 07054 (US). SIKORA, Joseph [US/US]; 16 Toby Drive, Succasunna, NJ 07876 (US). WANG, Barbara [US/US]; 19 Baldwin Drive, Berkeley Heights, NJ 07922 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PHARMACEUTICAL COMPOSITION COMPRISING 5-METHYL-2-(2'-CHLORO-6'-FLUOROANILINO)PHENYLACETIC ACID**

(57) Abstract: The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal in need of such treatment by parenteral administration of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof.

WO 2005/037266 A1